Loading...

Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 163.76 USD +0.06% Market Closed
Updated: Dec 6, 2022

Intrinsic Value

The intrinsic value of one ABBV stock under the Base Case scenario is 126.52 USD. Compared to the current market price of 163.76 USD, Abbvie Inc is Overvalued by 23%.

The Intrinsic Value is calculated as the average of the two valuation methods:

ABBV Intrinsic Value
Base Case
126.52 USD
Overvaluation 23%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

ABBV Profitability Score
Profitability Due Diligence

Abbvie Inc's profitability score is 75/100. The higher the profitability score, the more profitable the company is.

Declining ROIC
Negative Revenue Growth Forecast
Positive 1-Year Revenue Growth
Positive ROIC
75/100
Profitability
Score

Abbvie Inc's profitability score is 75/100. The higher the profitability score, the more profitable the company is.

ABBV Solvency Score
Solvency Due Diligence

Abbvie Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.

High D/E
Positive Net Debt
Average Interest Coverage
Average Altman Z-Score
33/100
Solvency
Score

Abbvie Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.

Financials
Efficiency
71%
Gross Margin
34%
Operating Margin
23%
Net Margin
38%
FCF Margin
91%
ROE
14%
ROIC
Other

ABBV Capital Structure
Abbvie Inc

Market Capitalization 290B USD
Total Debt 60.4B USD
Minority Interest 33M USD
Preferred Equity 0 USD
Cash and Equivalents 11.8B USD
Short-Term Investments 47M USD
Enterprise Value 338B USD

Wall St
Price Targets

ABBV Price Targets Summary
Abbvie Inc

Wall Street analysts forecast ABBV stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABBV is 162.63 USD with a low forecast of 134.33 USD and a high forecast of 210 USD.

Lowest
Price Target
134.33 USD
18% Downside
Average
Price Target
162.63 USD
1% Downside
Highest
Price Target
210 USD
28% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

ABBV Competitors
Abbvie Inc

ABBV Suppliers & Customers
Abbvie Inc

Abbvie Inc has 74 key suppliers from 13 countries and 11 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.

United States of America
49
Omnicom Group Inc
Media
ChargePoint Holdings Inc
Electrical Equipment
Monmouth Real Estate Investment Corp
Real Estate
Bristol-Myers Squibb Co
Pharmaceuticals
Model N Inc
Technology
Pfizer Inc
Pharmaceuticals
Box Inc
Technology
Catalent Inc
Pharmaceuticals
Merck & Co Inc
Pharmaceuticals
O
ON24 Inc
Technology
D
Diversified Healthcare Trust
Real Estate
P
PetIQ Inc
Health Care
Voyager Therapeutics Inc
Biotechnology
R
Royalty Pharma PLC
Pharmaceuticals
Regenxbio Inc
Biotechnology
Alphabet Inc
Media
Aptinyx Inc
Biotechnology
Halozyme Therapeutics Inc
Biotechnology
Reata Pharmaceuticals Inc
Pharmaceuticals
Exicure Inc
Biotechnology
CytomX Therapeutics Inc
Biotechnology
Enanta Pharmaceuticals Inc
Biotechnology
Kewaunee Scientific Corp
Health Care
Certara Inc
Health Care
Idera Pharmaceuticals Inc
Biotechnology
C
Cyteir Therapeutics Inc
Biotechnology
B
Beam Global
Electrical Equipment
Alector Inc
Biotechnology
Histogen Inc
Biotechnology
Personalis Inc
Life Sciences Tools & Services
TherapeuticsMD Inc
Pharmaceuticals
Chinook Therapeutics Inc
Biotechnology
Neurocrine Biosciences Inc
Biotechnology
Ironwood Pharmaceuticals Inc
Biotechnology
Editas Medicine Inc
Biotechnology
Myriad Genetics Inc
Biotechnology
Harvard Bioscience Inc
Life Sciences Tools & Services
Morphic Holding Inc
Biotechnology
Alpine Immune Sciences Inc
Biotechnology
Innodata Inc
Technology
OPTIMIZERx Corp
Health Care
T2 Biosystems Inc
Biotechnology
Syndax Pharmaceuticals Inc
Biotechnology
H
Harpoon Therapeutics Inc
Biotechnology
Oncternal Therapeutics Inc
Biotechnology
Paul Mueller Co
Machinery
I
Innovid Corp
Media
Seagen Inc
Biotechnology
SpringWorks Therapeutics Inc
Biotechnology
Suppliers Map

Abbvie Inc has 34 key customers from 6 countries and 4 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.

Ownership

ABBV Insider Trading
Buy and sell transactions by insiders

Abbvie Inc insiders have only sold shares in the past 12 months.

During the last 12 months Abbvie Inc insiders have not bought any shares, and sold 200M USD worth of shares. The last transaction was made on Dec 6, 2022 by Severino Michael (Vice Chairman), who sold 12M USD worth of ABBV shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
121M USD
4
9-12
months
72.1M USD
9
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
0
0 USD
9-12
months
0
0 USD
Cumulative Transactions Amount
Period Sold Bought Net
3 Months
N/A
N/A
N/A
6 Months
N/A
N/A
N/A
9 Months
121M USD
N/A
-121.5M
12 Months
194M USD
N/A
-193.6M
Purchases
19
Sales
133
Why is insider trading important?

Shareholder Return

ABBV Price
Abbvie Inc

1M 1M
+11%
6M 6M
+13%
1Y 1Y
+39%
3Y 3Y
+114%
5Y 5Y
+117%
Annual Price Range
163.76
52w Low
117.99
52w High
171.88
Price Metrics
Average Annual Return 7.18%
Standard Deviation of Annual Returns 12.5%
Max Drawdown -45%
Shares Statistics
Market Capitalization 290B USD
Shares Outstanding 1 768 480 000
Percentage of Shares Shorted 0.73%

Company Profile

Abbvie Inc

Country

United States of America

Industry

Biotechnology

Market Cap

290B USD

Dividend Yield

3.62%

Description

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 50,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products include Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The firm's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.

Contact

ILLINOIS
North Chicago
1 N Waukegan Rd
+18479327900.0
https://www.abbvie.com/

IPO

2013-01-02

Employees

50 000

Officers

Chairman & CEO
Mr. Richard A. Gonzalez
Vice Chairman & Pres
Mr. Robert A. Michael
Vice Chairman of External Affairs & Chief Legal Officer
Ms. Laura J. Schumacher
Exec. VP & Chief Commercial Officer
Mr. Jeffrey Ryan Stewart
Sr. VP & CFO
Mr. Scott T. Reents
Exec. VP of Operations
Dr. Azita Saleki-Gerhardt Ph.D.
Show More
Sr. VP of R&D and Chief Scientific Officer
Dr. Thomas J. Hudson
VP of Investor Relations
Ms. Elizabeth Shea
Exec. VP, Gen. Counsel & Sec.
Mr. Perry C. Siatis
Exec. VP & Chief HR Officer
Mr. Timothy J. Richmond
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one ABBV stock?

The intrinsic value of one ABBV stock under the Base Case scenario is 126.52 USD.

Is ABBV stock undervalued or overvalued?

Compared to the current market price of 163.76 USD, Abbvie Inc is Overvalued by 23%.